{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007430","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.023204+00:00","generated_at":"2026-05-16T01:42:07.200931+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cocrystal Pharma's CDI-988 oral norovirus inhibitor to be featured at ICAR 2026","bullets":["CDI-988 is the first oral antiviral drug candidate developed for prevention and treatment of norovirus infections.","Company to present Phase 1b challenge study data at ICAR 2026 in Prague (Apr 27-May 1, 2026).","No approved antiviral therapies or vaccines for norovirus; estimated $10.6B annual US economic burden.","CDI-988 is a pan-viral protease inhibitor also targeting coronaviruses, developed using proprietary structure-based platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007430","json":"https://secwatch.observer/filing/0001493152-26-007430.json","markdown":"https://secwatch.observer/filing/0001493152-26-007430.md","text":"https://secwatch.observer/filing/0001493152-26-007430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226007430/0001493152-26-007430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226007430/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:42:07.200931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}